Obstacles on the German path for Wayland Group. The company announced last week to be one of the three companies to have won German cultivation licenses, with Aphria and Aurora being the other ones. However as was announced today, the licenses awarded to the Wayland - DEMECAN joint venture remain under review. "As they have been challenged by a third party," the company explains.
"Earlier today, the German Federal Institute for Drugs and Medical Devices (BfArM) announced that 9 of the 13 cultivation licenses that were previously announced have been officially awarded. Wayland, through its joint venture with DEMECAN GmbH, was originally selected by BfArM to receive three licenses to produce medical cannabis in Germany", they explain. Per the announcement, four licenses remain under review.
According to German media, an unidentified bidder who lost out is challenging the procedure with a regulator.
The company states: "Wayland’s quality concept received 60 out of 60 points for quality and 40 out of 40 points for price. We believe in our concept and do not believe there is merit to the complaints. Wayland fully expects that the award of three lots to DEMECAN will be confirmed."
Aphria Germany had won five of the 13 lots. One lot stands for an annual amount of 200 kilograms of cannabis flowers per year, five lots for one ton.
Aurora was also awarded the maximum number of 5 of the 13 lots in the tender over a period of four years with a minimum supply of 4000kg total. They are pretty excited to start building. "The approval will allow Aurora to begin construction of a new, state-of-the art, indoor cannabis production facility in Leuna, Germany in May 2019 and we anticipate completion within 12 months of ground breaking. Initial shipments of locally grown cannabis are expected to become available to German medical patients starting in October 2020, with the new facility producing a minimum of 4,000 kg over a four-year period, to be expanded over time as regulations permit", they say.